

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	10/19/1961
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Prostate Specific Antigen, Total

Prostate Specific Antigen, Total	0.9 ng/mL INTERPRETIVE INFORMATION: Pr	(Ref Interval: 0.0-4.0) rostate Specific Antigen
	Results obtained with differ used interchangeably. The Ro as an aid in the detection of conjunction with a digital r prostate age 50 years and of for the serial measurement of management of prostate cance concentrations can only sugg until biopsy is performed. F elevated in benign prostatic conditions of the prostate.	uminescent immunoassay is used. rent test methods or kits cannot be oche PSA method is approved for use of prostate cancer when used in rectal exam in individuals with a lder. The Roche PSA is also indicated of PSA to aid in the prognosis and er patients. Elevated PSA gest the presence of prostate cancer PSA concentrations can also be c hyperplasia or inflammatory PSA is generally not elevated in viduals with nonprostatic carcinoma.

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Prostate Specific Antigen, Total	22-361-113450	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director